Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04898946
  4. Details
NCT04898946 Clinical Trial

Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

Covid-19 Vaccine Clinical Trial

Official title:
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04898946
Other study ID # Covid-19 Vaccine Antibody
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 7, 2021
Est. completion date December 31, 2021

Study information
Verified date February 2024
Source Hong Kong Sanatorium & Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Since the first local case of COVID-19 confirmed on 4 Feb 2020, Hong Kong has already experienced 4 waves of COVID-19 surge, with more than 9000 cases reported. A number of vaccines have been shown to be efficacious against symptomatic and severe infection by inducing neutralizing antibody (NAB) against spike protein of the SARS-CoV-2 virus. However, the duration of protection and longevity of antibody response is unknown. Health care workers (HCWs) who are planning to receive COVID-19 vaccine will be recruited. The level of antibody against spike protein by different quantitative assays will also be serially measured .

Recruitment information / eligibility
Status Completed
Enrollment 480
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Any staff, visiting doctor, nursing student of HKSH who are aged 18 or above 2. No contraindication for COVID-19 vaccination and plan to receive the intended dosages at the appropriate interval. 3. A baseline serology taken within 1 week before vaccination shows no evidence of recent infection. 4. No history of documented COVID-19 infection Exclusion Criteria: -

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• CoronaVac Vaccine
CoronaVac Vaccine
• BNT162b2 Vaccine
Covid-19 BNT162b2 Vaccine

Locations
Country Name City State
Hong Kong Hong Kong Sanatorium & Hospital Hong Kong

Sponsors (1)
Lead Sponsor Collaborator
Hong Kong Sanatorium & Hospital

Country where clinical trial is conducted

Hong Kong, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change of IgG Level in the serum of healthcare workers who received COVID-19 vaccine Change of IgG Level in the serum of healthcare workers who received COVID-19 vaccine at different points during the first six months of vaccination 1 month, 3 months and 6 months post vaccination
See also
  Status Clinical Trial Phase
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Recruiting NCT05998824 - COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease N/A
Recruiting NCT05097053 - A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 Phase 4
Active, not recruiting NCT05463419 - A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. Phase 2/Phase 3
Active, not recruiting NCT05293223 - Phase IIB Study of Recombinant Novel Coronavirus Vaccine Phase 2
Completed NCT04691947 - Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC Phase 1
Completed NCT05288231 - Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
Completed NCT04546841 - Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults Phase 1
Recruiting NCT04963790 - Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake N/A
Completed NCT05216601 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 Phase 1
Completed NCT04566276 - ChulaCov19 Vaccine in Healthy Adults Phase 1/Phase 2
Completed NCT04915820 - Iron and COVID-19 Vaccine Response N/A
Completed NCT05268679 - Covid-19 Vaccine Response in Heart Transplant Recipients
Recruiting NCT05869968 - SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Active, not recruiting NCT05197712 - Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease Phase 1
Recruiting NCT05553743 - Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
Active, not recruiting NCT05188469 - Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers Phase 1/Phase 2
Completed NCT04764422 - Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Phase 1/Phase 2
Recruiting NCT04838080 - Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo Phase 1
Recruiting NCT05822219 - Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases N/A